Last $53.86 USD
Change Today -0.75 / -1.37%
Volume 722.6K
ALNY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Judy Lieberman M.D., Ph.D.

Member of Scientific Advisory Board, Alnylam Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 30 board members in 2 different organizations across 2 different industries.

See Board Relationships
----

Background*

Dr. Judy Lieberman, M.D., Ph.D. is Professor of pediatrics at the Harvard Medical School, Director of the Division of AIDS at Harvard Medical School, and a senior investigator in the Immune Disease Institute. Dr. Lieberman is board certified in internal medicine and hematology, a widely known expert in translational medicine, and a pioneer in the therapeutic use of RNAi, particularly through the development of innovative delivery tools. Dr. Lieberman and her colleagues ...

Read Full Background

Corporate Headquarters*

300 Third Street
Cambridge, Massachusetts 02142

United States

Phone: 617-551-8200
Fax: 617-551-8101

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

MD
Harvard University
MD
Massachusetts Institute of Technology
PhD
Rockefeller University

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $53.86 USD -0.75

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
4.0K GBP
George W. Hebard III, M.B.AInterim Principal Executive Officer and Interim Chief Operating Officer
Enzon Pharmaceuticals Inc.
$226.4K
Mark J. Ahn Ph.D.Chief Executive Officer, President and Director
Galena Biopharma, Inc.
$664.9K
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year 2012.

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.